News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Warns of Birth Defects with Use of Johnson & Johnson’s Topamax
March 7, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - An epilepsy drug also used to help prevent migraines can increase the risk for oral birth defects in babies born to women taking the medication, U.S. health officials said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Johnson & Johnson Family of Companies
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Drug pricing
Trump Calls on Congress To Codify Most Favored Nation Drug Pricing in SOTU
February 25, 2026
·
2 min read
·
Annalee Armstrong
Vaccines
Postponed ACIP Meeting Rescheduled for Mid-March
February 25, 2026
·
3 min read
·
Tristan Manalac
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
February 23, 2026
·
3 min read
·
Nick Paul Taylor
Government
Kennedy Ally Departs CDC Amid Leadership Shake-Up
February 23, 2026
·
1 min read
·
Annalee Armstrong